DEVELOPMENT OF A FENTANYL PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL AND EVALUATION OF DRUG-DRUG INTERACTIONS WITH TRIAZOLE ANTIFUNGAL AGENTS.

被引：0
|
作者：
Carreno, F. [1 ]
Edginton, A. [2 ]
Gonzalez, D. [1 ]
机构：
[1] Univ North Carolina Chapel Hill, Chapel Hill, NC USA
[2] Univ Waterloo, Waterloo, ON, Canada
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2021年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIII-033
引用
收藏
页码：S54 / S54
页数：1
相关论文
共 50 条
  • [1] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING (PBPK) OF PITAVASTATIN AND ATORVASTATIN TO PREDICT DRUG-DRUG INTERACTIONS (DDIS).
    Duan, P.
    Zhao, P.
    Zhang, L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S16 - S17
  • [2] Physiologically-Based Pharmacokinetic Model Development, Validation, and Application for Prediction of Eliglustat Drug-Drug Interactions
    Sahasrabudhe, Siddhee A.
    Cheng, Shen
    Al-Kofahi, Mahmoud
    Jarnes, Jeanine R.
    Weinreb, Neal J.
    Kartha, Reena, V
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (06) : 1254 - 1263
  • [3] Physiologically-based Pharmacokinetic (PBPK) Modelling of Transporter Medi-ated Drug Absorption, Clearance and Drug-drug Interactions
    Taskar, Kunal S.
    Harada, Isobel
    Alluri, Ravindra, V
    [J]. CURRENT DRUG METABOLISM, 2021, 22 (07) : 523 - 531
  • [4] A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR SIMULATION OF NALOXEGOL PHARMACOKINETICS AND DRUG-DRUG INTERACTION (DDI) POTENTIAL
    Zhou, D.
    Bui, K.
    Sostek, M.
    Al-Huniti, N.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S53 - S53
  • [5] Physiologically-Based Pharmacokinetic Model-Informed Drug Development for Fenebrutinib: Understanding Complex Drug-Drug Interactions
    Chen, Yuan
    Ma, Fang
    Jones, Nicholas S.
    Yoshida, Kenta
    Chiang, Po-Chang
    Durk, Matthew R.
    Wright, Matthew R.
    Jin, Jin Yan
    Chinn, Leslie W.
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2020, 9 (06): : 332 - 341
  • [6] Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions
    de Kanter, Ruben
    Sidharta, Patricia N.
    Delahaye, Stphane
    Gnerre, Carmela
    Segrestaa, Jerome
    Buchmann, Stephan
    Kohl, Christopher
    Treiber, Alexander
    [J]. CLINICAL PHARMACOKINETICS, 2016, 55 (03) : 369 - 380
  • [7] QUALIFICATION AND APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING AND SIMULATION (MANDS) TO PREDICT DRUG-DRUG INTERACTIONS FOR ALISERTIB
    Patel, C.
    Ananthula, H.
    Zhou, X.
    Xia, C.
    Chowdhury, S.
    Zhu, A.
    Pusalkar, S.
    Venkatakrishnan, K.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S82 - S82
  • [8] PREDICTION OF DRUG-DRUG INTERACTIONS (DDI) WITH A MODERATE CYP3A INDUCER: DEVELOPMENT AND VALIDATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL OF RIFABUTIN
    Sorour, M.
    Mundra, V.
    Zhang, H.
    Sahasranaman, S.
    Ou, Y.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S75 - S75
  • [9] Physiologically-based pharmacokinetic modeling of prominent oral contraceptive agents and applications in drug-drug interactions
    Lewis, Gareth J.
    Ahire, Deepak
    Taskar, Kunal S.
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (04): : 563 - 575
  • [10] PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING OF ELAGOLIX FOR PREDICTION OF DRUG-DRUG INTERACTIONS (DDIS)
    Chiney, M. S.
    Polepally, A. R.
    Nader, A. M.
    Dufek, M. B.
    Klein, C. E.
    Ng, J. W.
    Shebley, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S59 - S59
12345